COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function. - Wikidata - wikimedia - TriplyDB

COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function.

COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function.

http://www.wikidata.org/entity/Q33678308

about

The Potential Protective Effects of Polyphenols in Asbestos-Mediated Inflammation and Carcinogenesis of Mesothelium Paving the Road to Tumor Development and Spreading: Myeloid-Derived Suppressor Cells are Ruling the Fate Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy COX-2 and PGE2-dependent immunomodulation in breast cancer Myeloid-derived suppressor cells as therapeutic target in hematological malignancies Update on the challenges and recent advances in cancer immunotherapy Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy Immunosuppression associated with chronic inflammation in the tumor microenvironment Mesothelioma response to carbon nanotubes is associated with an early and selective accumulation of immunosuppressive monocytic cells Coordinated regulation of myeloid cells by tumours The emerging immunological role of post-translational modifications by reactive nitrogen species in cancer microenvironment Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer.Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4(+)IL17(+) response.TLR/MyD88-mediated Innate Immunity in Intestinal Graft-versus-Host Disease Downregulation of CD40 expression contributes to the accumulation of myeloid-derived suppressor cells in gastric tumors.New roads open up for implementing immunotherapy in mesothelioma.Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells.Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment.Intermittent chemotherapy can retain the therapeutic potential of anti-CD137 antibody during the late tumor-bearing state.Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells.6-Thioguanine-loaded polymeric micelles deplete myeloid-derived suppressor cells and enhance the efficacy of T cell immunotherapy in tumor-bearing mice.Finasteride Enhances the Generation of Human Myeloid-Derived Suppressor Cells by Up-Regulating the COX2/PGE2 Pathway Molecular pathways: tumor-infiltrating myeloid cells and reactive oxygen species in regulation of tumor microenvironment Correlation between circulating myeloid-derived suppressor cells and Th17 cells in esophageal cancer.Transcriptional regulation of myeloid-derived suppressor cells.Myeloid-derived suppressor cells from tumor-bearing mice impair TGF-β-induced differentiation of CD4+CD25+FoxP3+ Tregs from CD4+CD25-FoxP3- T cells Repurposing Drugs in Oncology (ReDO)-diclofenac as an anti-cancer agent Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts.Immunotherapy in pediatric malignancies: current status and future perspectives An inflammatory mediator, prostaglandin E2, in colorectal cancer.Microenvironment generated during EGFR targeted killing of pancreatic tumor cells by ATC inhibits myeloid-derived suppressor cells through COX2 and PGE2 dependent pathway.Myeloid derived suppressor cells: Targets for therapy.Activated hepatic stellate cells promote liver cancer by induction of myeloid-derived suppressor cells through cyclooxygenase-2.Murine mesothelioma induces locally-proliferating IL-10(+)TNF-α(+)CD206(-)CX3CR1(+) M3 macrophages that can be selectively depleted by chemotherapy or immunotherapy.Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.Potential therapeutic anti-tumor effect of a Salmonella-based vaccine.Pancreatic Cancer Cells Isolated from Muc1-Null Tumors Favor the Generation of a Mature Less Suppressive MDSC Population.Dendritic cells in the pathogenesis and treatment of human diseases: a Janus Bifrons?

P2860

Q26750451-4AE6E6AC-5BE4-452A-BF73-4EF76D841949 Q26777205-4BB0485D-2AF7-4E28-B945-F3DE533D439A Q26863418-3CA1A5B5-6BE1-4F74-8737-AA4ABD4B7E7F Q26996829-C5CDF69C-A14D-43F6-8C51-205D56F24238 Q27002646-10B281EE-7524-4DDB-BD37-984F343ACF24 Q27003937-2276E85B-C0E1-4B34-AEB6-F31A7402B856 Q27010234-BAE9DABB-1270-4D8D-A05D-F86DB48820C2 Q27014693-A660BDFD-4466-48EE-ABC6-094FCFB7CFF4 Q28082461-12FB044D-1847-4004-BC97-0B1D5F5AF775 Q28083450-45861E46-4B63-415C-9E9E-2A8A77F7A4E4 Q28387268-75579093-0222-4825-A1E6-4C995B09D56E Q28395157-0C1675BE-8E60-4BE2-94A0-797B4CB5C18B Q28396481-5DC517F2-9774-4249-B5C1-BDC28935695C Q33606107-A92E42E1-CC4E-4341-A453-4ECE53FBBA65 Q33606132-BFA7D0A6-1270-4EEA-8198-43EF692AAD03 Q33835099-87D9C71D-DD7D-4179-BF25-D9CB76778230 Q33844271-0385B6DC-F16A-47F2-9461-3FE50ED00684 Q34331993-B1864C05-3B51-4E42-944A-4373AD55BD28 Q34457611-9466BA95-E73E-4E8A-BFB4-DDC999C3CA9C Q34502899-BB13EFD7-B779-4FF8-A128-4C2DC860A8DC Q35051306-79632101-F733-46A7-ADDD-E94E83CFA686 Q35553327-714DDB01-EC5E-4949-A12F-8BDC8F383BB2 Q35863346-CEC39B9E-A4F6-4AEA-A332-7B1494302A00 Q36037921-B3552F3B-8A01-47AA-A149-A31B2B6A930C Q36243616-1DFF9D5C-4B29-44FE-BA5E-0062908353E5 Q36316728-F16545B8-9940-474E-846D-68316FC19FE5 Q36322351-AAF05660-3788-44B5-99BF-8E7FCEA6D4DA Q36332711-EAF344AE-4ACA-449A-B181-E3E14B96997F Q36483712-574D6F0E-485A-401B-A97B-02C5592475FB Q36594073-5684C4DC-A315-4DA8-ADAE-FE96A89443FA Q36691818-CC2B96FC-482A-4B67-9945-E394556E525D Q36701908-38E34CB4-14C2-49D0-9507-154BAF55E862 Q36718698-B6814959-167A-42DF-8DF9-058331961A14 Q36845851-C8BFD913-530A-46EF-8CD3-EB1DE924ED8C Q36962436-14062E8E-D46C-405B-8614-F752C1D28927 Q37078960-176C85A5-0847-4D4D-B7BF-990CA67038A7 Q37079141-DC96883A-08B7-427A-9C2D-473D0D040A65 Q37530067-ED620049-C7A1-4303-BD57-E228C380F9FD Q37598872-517EBC0F-F19C-44B9-91FC-A5975ED7195C Q37945301-0D0AB406-62D5-4F8A-A658-F44BE41C6E2C

P2860

COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function.

http://www.wikidata.org/entity/Q33678308

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

COX-2 inhibition improves immu ...... oxib influences MDSC function.

@ast

COX-2 inhibition improves immu ...... oxib influences MDSC function.

@en

type

label

COX-2 inhibition improves immu ...... oxib influences MDSC function.

@ast

COX-2 inhibition improves immu ...... oxib influences MDSC function.

@en

prefLabel

COX-2 inhibition improves immu ...... oxib influences MDSC function.

@ast

COX-2 inhibition improves immu ...... oxib influences MDSC function.

@en

P1433

Q33678308-74AA5115-B210-4A96-8BF5-F0D9881C0861

P1476

Q33678308-736A280C-9AD9-48DF-B1B4-4C315473AD0E

P2093

Q33678308-30D9A1A3-BC68-42F6-B2DC-EC7E56813AA0

Q33678308-4965789E-17B1-4E7E-8EF6-B22D91C547BC

Q33678308-65B77380-FDA9-4599-98A4-DAAFDEC08E82

Q33678308-8947A76E-D940-41AE-894F-DE8D7CF39B37

Q33678308-B5AAB890-22B4-4712-A772-28C714DD37E4

Q33678308-BCCA51F2-E0DC-4E3F-873D-95EA5D9717B8

Q33678308-C1321EFA-CB68-4E03-B981-4B7E6D8209CC

P2860

Q33678308-034E07AC-17FC-4FE6-99CA-31858F7C5DB9

Q33678308-08983E5B-8A75-40D0-9F4B-111E96524E79

Q33678308-0A350586-43C7-4466-83DC-0EBEBAA8EB9F

Q33678308-18FD442E-A2D7-44E4-93EA-478E9008E09F

Q33678308-19DB9CBF-5FE3-44B5-AB4D-182FBD4B462B

Q33678308-1B9CF196-1041-4D68-AD20-72659D7F0EC3

Q33678308-1FD213B8-9771-451E-A840-21231D6BA595

Q33678308-2E7CD956-55EE-4F0E-912C-0C5A0D326A70

Q33678308-340654A4-4552-425B-8E32-4F43065A84A7

Q33678308-44E7FA83-9AD5-4533-9BC1-5919CDD30289

P2888

Q33678308-9CE00A97-52A9-475A-A6BF-3B40A647BB8B

P304

Q33678308-3E8255B4-C447-4D80-9D1E-9BBC96A3A3E5

P31

Q33678308-D0AA7B2E-7E67-45F8-A0C0-908B6949F8C6

P356

Q33678308-AE2665B3-82EA-44D3-8A99-75A82EC3A51C

P407

Q33678308-041AF6B3-364A-410F-BE90-4B6827974231

P478

Q33678308-263449CF-C373-4B3F-9601-3F05396EFAD8

P577

Q33678308-E06FB4D4-90E2-4C4D-84F3-8E3FDE114E74

P5875

Q33678308-34EB7018-AFDA-48D1-B713-0F4DC3FCBA87

P6179

Q33678308-765DDFF1-7DB5-4D7B-BEC3-D82BDC8B5BBD

P698

Q33678308-1745E901-01A9-4C7F-B1F3-B941E95B3D98

P921

Q33678308-3BC36ABA-FD8F-4647-9D2B-E2FC47454CA7

P932

Q33678308-12EF9E5D-7370-476B-8B6E-E1F30EAC8BB1

P356

1471-2407-10-464

P1433

P1476

COX-2 inhibition improves immu ...... oxib influences MDSC function.

@en

P2093

Henk C Hoogsteden

http://www.w3.org/2001/XMLSchema#string

Joachim G J V Aerts

http://www.w3.org/2001/XMLSchema#string

Joost P J J Hegmans

http://www.w3.org/2001/XMLSchema#string

Joris D Veltman

http://www.w3.org/2001/XMLSchema#string

Margaretha E H Lambers

http://www.w3.org/2001/XMLSchema#string

Menno van Nimwegen

http://www.w3.org/2001/XMLSchema#string

Rudi W Hendriks

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer-related inflammation

Myeloid-derived suppressor cells as regulators of the immune system

Celecoxib for the prevention of colorectal adenomatous polyps

Cyclooxygenases in cancer: progress and perspective

Regulation of immune responses by L-arginine metabolism

Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial.

Mechanism of T cell tolerance induced by myeloid-derived suppressor cells.

Prostaglandin E(2) regulates the level and stability of cyclooxygenase-2 mRNA through activation of p38 mitogen-activated protein kinase in interleukin-1 beta-treated human synovial fibroblasts.

Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance.

Immature myeloid cells and cancer-associated immune suppression.

P2888

1471-2407-10-464

P304

464

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-10-464

http://www.w3.org/2001/XMLSchema#string

P407

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2010-08-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46094565

http://www.w3.org/2001/XMLSchema#string

P6179

1053035444

http://www.w3.org/2001/XMLSchema#string

P698

20804550

http://www.w3.org/2001/XMLSchema#string

P921

P932

2939552

http://www.w3.org/2001/XMLSchema#string